TPTE and cancer: The FixVac BNT111 vaccine, which BioNTech is developing, is one example of an mRNA cancer vaccine that targets four melanoma TAAs, including tyrosinase, melanoma antigen family A3 (MAGE A3), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), and transmembrane phosphatase with tensin homology (TPTE) [99].